Status:
COMPLETED
MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Neutropenia
Fever
Eligibility:
All Genders
2-17 years
Phase:
PHASE2
Brief Summary
This study is a double-blind, randomized study of MK0991 versus liposomal amphotericin B in the empirical treatment of pediatric patients (ages 2 through 17 years) who have an absolute neutrophil coun...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients who are 2 through 17 years of age
- Absolute Neutrophil Count (ANC) is below 500/microliter
- Have persistent fever (at least 4 days) despite antibiotic therapy
Exclusion
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2006
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00082537
Start Date
April 1 2004
End Date
October 1 2006
Last Update
February 23 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.